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Abstract
Although nephron-sparing surgery (NSS) has demonstrated benefit in terms of renal
function preservation, it is unclear whether NSS might also decrease the risk of end-
stage renal disease (ESRD) relative to radical nephrectomy (RN). In the current paper, we
aimed to report the rate and the predictors of ESRD after surgery, accounting for detailed
individual baseline characteristics and comorbidities. A multi-institutional collabora-
tion among five European tertiary care centers allowed study of 2027 patients with
normal preoperative renal function and a clinically localized T1abN0M0 renal mass. Cox
regression analyses were used to predict the risk of ESRD (defined as the onset of a
postoperative estimated glomerular filtration rate <15 ml/min per 1.73 m2) after
adjusting for the individual baseline risk of developing chronic kidney disease. Uni-
variable ESRD rates at 5 and 10 yr of follow-upwere virtually equivalent for patientswho
underwent NSS (1.5% and 2.5%, respectively) versus RN (1.9% and 2.7%, respectively;
hazard ratio [HR]: 0.8; 95% confidence interval [CI], 0.4–1.6). However, diabetes,
smoking, uncontrolled hypertension, and other comorbidities were consistently more
frequent in the NSS group relative to their RN counterparts. After adjusting for detailed
baseline individual characteristics, NSS was shown to have an independent protective
effect relative to RN (HR: 0.4; 95% CI, 0.2–0.8; p = 0.02) at multivariable analyses.
Patient summary: After accounting for individual baseline characteristics, such as age,
diabetes, uncontrolled hypertension, or other comorbidities, partial nephrectomy inde-
pendently protects against end-stage renal disease and the consequent need for dialysis
relative to radical nephrectomy.
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represents the standard of care for patients diagnosed with
a clinically localized renal mass [1], mainly due to a
demonstrated benefit in terms of preservation of renal
function [2]. In a recent subanalysis of 514 patients included
in the European Organization for Research and Treatment of
Cancer (EORTC) randomized trial 30904, the incidence of
end-stage renal disease (ESRD) was nearly identical for
patients treated with either NSS or radical nephrectomy
(RN) [2]. In the current paper, we aimed to report the rate
and the predictors of ESRD after renal surgery. To limit the
inherent risk of bias, we investigated a large multi-
institutional data set that allowed adjustment for a detailed
panel of intrinsic confounders such as uncontrolled
hypertension, diabetes, body mass index (BMI), and other
comorbidities.
The current study relied on a collaborative database
collected from five European tertiary care centers. Patients
with a primary diagnosis of nonmetastatic clinical T1
unilateral kidney cancer without a baseline condition of
chronic kidney disease who were treated with NSS or RN
between 1984 and 2010 were included. The outcome of the
study was ESRD, defined as the onset of a postoperative
estimated glomerular filtration rate (GFR) <15 ml/min per
1.73 m2. GFR was calculated by the Chronic Kidney Disease
Epidemiology Collaboration formula in younger patientsTable 1 – Clinical characteristics of 2027 patients with cT1N0M0 renal
either nephron-sparing surgery or radical nephrectomy, stratified by t
Variable NSS (n = 1
Clinical characteristics
Age,yr, median (IQR) 61 (51–
Gender, %
Male 66.0
Female 34.0
eGFR before surgery, ml/min/1.73 m2, median (IQR) 86 (82–
Body mass index, median (IQR) 25.7 (2
Smoking status, %
No 59.2
Smoker 27.3
Former 13.6
Diabetes, % 12.5
Hypertension, %
No 56.5
Uncontrolled 21.1
Controlled by therapy 22.4
Charlson comorbidity index, %
0 45.3
1 16.2
>1 38.6
Clinical tumor size, median (IQR) 3.2 (2
Surgical characteristics
Ischemia time, min, median (IQR) 11 (0–1
Type of ischemia, %
No ischemia 32.4
Warm ischemia 66.9
Cold ischemia 0.8
Open, n (%) 889 (66.
Laparoscopic, n (%) 315 (23.
Robotic, n (%) 130 (9.7
eGFR = estimated glomerular filtration rate; IQR = interquartile range; NA = not a
Mann-Whitney and chi-square tests were used to compare the statistical significa
respectively.(aged <70 yr) and by the Berlin Initiative Study formula in
older patients (aged 70 yr) [3]. We included the following
covariates: age, year of surgery, preoperative GFR, tumor
size, hypertension (none, uncontrolled, or controlled by
medical therapy), diabetes, baseline Charlson comorbidity
index (CCI), BMI, and smoking status (no, yes, or former).
First, descriptive statistics were reported. Second, multi-
variable Cox regression analyses were used to assess the
impact of surgery type (NSS vs RN) on ESRD after
adjustment for all available covariates. Finally, multivari-
able Cox regression coefficients were used to plot the
covariate-adjusted ESRD rates according to different patient
subgroups.
Overall, 2027 patients were included in the study
(Table 1). Patients were treated with NSS (65.8%,
n = 1334) or RN (34.2%, n = 693). Patients treated with
NSS were more frequently diagnosed with concomitant
comorbidities (CCI0; 55% vs 40%; p< 0.001), uncontrolled
hypertension (21% vs 13%; p < 0.001), diabetes (12% vs 7%;
p < 0.001), and smaller tumor (32 vs 50 mm; p < 0.001)
(Table 1). Mean follow-up was 72 mo. Supplementary
Figure 1 depicts ESRD events according to treatment type.
Median time to ESRD was 45 mo (interquartile range:
19–106mo). Unadjusted ESRD rates at 5 and 10 yr of follow-
up were virtually equivalent between patients who under-
went NSS (1.5% and 2.5%, respectively) versus RN (1.9% andtumor with normal renal function before surgery and treated with
reatment delivery
334, 65.8%) RN (n = 693, 34.2%) p value
69) 61 (52–69) 0.4
0.9
66.2
33.8
98) 85 (85–93) 0.002
3.8–27.9) 25.8 (23.8–27.9) 0.7
<0.001
53.1
22.6
19.8
7.4 <0.001
<0.001
67.2
13.3
19.5
<0.001
60.0
18.2
21.7
.5–4.0) 5.0 (3.7–6.0) <0.001
8) NA NA
NA NA
6) 615 (88.7) <0.001
6) 78 (11.7)
) 0 (0)
pplicable; NSS = nephron-sparing surgery; RN = radical nephrectomy.
nce of differences in the distribution of continuous and categorical variables,
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 5 5 8 – 5 6 15602.7%, respectively; p = 0.5; hazard ratio [HR]: 0.8; 95%
confidence interval [CI], 0.4–1.6) (Supplementary Fig. 1).
Age (p < 0.001; HR: 1.1; 95% CI, 1.1–1.1), presence of
diabetes (p = 0.002; HR: 3.4; 95% CI, 1.5–7.4), uncontrolled
hypertension (p < 0.001; HR: 4.1; 95% CI, 2.1–8.2), and CCI
(>1 vs 0; p = 0.004; HR: 3.4; 95% CI, 1.5–7.8) were
associated with ESRD risk (Supplementary Table 1). At
multivariable analyses, after adjusting for all detailed
baseline individual characteristics, NSS showed an inde-
pendent protective effect against ESRD relative to RN (HR:
0.4; 95% CI, 0.2–0.8; p = 0.02) (Supplementary Table 1).
Figure 1 shows the multivariate-derived ESRD cumulative
rates according to treatment type, patient age, diabetes, and
hypertension, which, alongside year of surgery, were the
most informative predictors of ESRD (Supplementary
Table 1).
ESRD is a life-threatening condition [4]. In young and
healthy persons, the estimated risk of ESRD at 15 yr is 0.04%
(95% CI, 0.008–0.09), reaching a peak of 0.3% (95% CI, 0.2–
0.4) in healthy kidney donors [5]. Due to older age, high
prevalence of associated comorbidities, and reduced[(Fig._1)TD$FIG]
Fig. 1 – Adjusted ESRD cumulative rates stratified by (a) treatment delivery (N
(none, controlled by medical therapy, or uncontrolled). Data are corrected for
preoperative estimated glomerular filtration rate, Charlson comorbidity index
ESRD = end-stage renal disease; NSS = nephron-sparing surgery; RN = radical nenumber of nephrons, ESRD risk after surgery for renal
cancer is significantlymore common. In such settings, ESRD
has been already been prospectively reported in the EORTC
trial 30904, showing rates very similar to the current report
(1.5–1.6% at a median follow-up of 6.7 yr) and demonstrat-
ing no difference in terms of ESRD rates between patients
treated with NSS and RN (–0.1%, 95% CI, –2.2 to 2.1) [2].
Although many limitations affected the original trial (eg,
limited recruitment, crossover treatment, and lack of
detailed comorbidity data of the patients), the EORTC trial
suggested that ESRD might be related to intrinsic factors
(eg medical conditions such as diabetes) that cannot be
amended by the type of surgical technique delivered. That
said, the current findings cannot be completely compared
with the EORTC trial 30904. The randomized study included
patients treated before 2003, some with preoperative
renal function impairment (roughly 10%) and with limited
surgical experience in terms of NSS techniques and
outcomes. The current series included patients who were
treated more recently, who had normal preoperative renal
function (in all patients treated), and who did not have hilarSS vs RN), (b) patient age, (c) presence of diabetes, and [2_TD$DIFF](d) hypertension
age, year of surgery, body mass index, clinical tumor size, hypertension [1_TD$DIFF],
, diabetes, and smoking status.
phrectomy.
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(Table 1). Those main differences may explain the discor-
dance between the benefit we found in the NSS group
and the EORTC trial findings. In addition, Lin et al reported
similar findings in a recent nationwide population-based
study, although they could not adjust their findings for
important determinants of chronic kidney disease, such as
the presence of uncontrolled hypertension, BMI, and
smoking status [6]. Finally, Yap et al recently anticipated
a beneficial effect of NSS in decreasing the risk of ESRD (HR:
0.44; 95% CI, 0.25–0.75), although they could not adjust the
results for tumor characteristics (eg, tumor size, TNM),
which aremain determinants for surgical indication (NSS vs
RN) and survival outcomes [7].
The current report introduces key findings. Considering
the important causes of ESRD, such as diabetes, uncon-
trolled hypertension, and age, NSS appears to decrease the
probability of ESRD after surgery. An even greater benefit is
possible with the novel surgical techniques of no clamp or
selective clamping, which were recently reported [1]. As
already verified by others [8], baseline medical conditions
that may produce renal functional impairment remain the
key and most informative causes of renal failure, regardless
of all surgical efforts to preserve nephrons [9]. However, our
findings also corroborate the beneficial effect of NSS for the
consequences of a baseline medical condition favoring
chronic kidney disease [9].
The current study has several strengths, including the
multi-institutional design, the relatively long follow-up,
and the inclusion of patients without a condition of baseline
chronic kidney disease. However, despite its appeal and
uniqueness, the current study is not devoid of limitations,
mainly due to the retrospective design of the study, which
cannot exclude the presence of residual confounders (eg,
proteinuria at diagnosis).
In conclusion, roughly 2% of the patients with normal
estimated GFR before kidney surgery will develop ESRD in
the first 10 yr of follow-up. In addition to the already known
protective benefits in terms of cardiovascular events and
renal function preservation, NSS seems to be associatedwith
a lower risk of ESRD relative to RN. Nonetheless, individual
risk factors inherent at baseline (especially age, diabetes, and
uncontrolledhypertension) appear to be crucial predictors of
ESRD regardless of the treatment delivered.
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